Profile data is unavailable for this security.
About the company
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
- Revenue in AUD (TTM)0.00
- Net income in AUD-149.68m
- Incorporated1986
- Employees0.00
- LocationImugene LtdSuite 804, Level 8, 37 Bligh StreetSYDNEY 2000AustraliaAUS
- Phone+61 39824-5254
- Fax+61 39822-7735
- Websitehttps://www.imugene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paradigm Biopharmaceuticals Ltd | 6.52m | -58.65m | 82.31m | -- | -- | 3.46 | -- | 12.62 | -0.1875 | -0.1875 | 0.0186 | 0.068 | 0.138 | -- | 1.10 | -- | -124.19 | -52.89 | -150.28 | -58.06 | 99.86 | -- | -899.60 | -543.63 | -- | -961.47 | 0.006 | -- | -23.22 | 14.97 | -12.99 | -- | -- | -- |
| Actinogen Medical Ltd | 291.02k | -13.04m | 84.09m | -- | -- | 4.28 | -- | 288.94 | -0.0061 | -0.0061 | 0.0001 | 0.0072 | 0.0159 | -- | 0.0433 | -- | -71.44 | -48.56 | -78.20 | -51.97 | -- | -- | -4,482.26 | -5,188.44 | -- | -163.10 | 0.0159 | -- | -20.63 | 7.31 | -21.32 | -- | -- | -- |
| Proteomics International LaboratoriesLtd | 1.41m | -6.38m | 85.15m | -- | -- | 9.04 | -- | 60.41 | -0.0507 | -0.0507 | 0.0112 | 0.0719 | 0.1346 | -- | 6.45 | -- | -61.88 | -60.46 | -67.65 | -69.49 | -- | -- | -459.82 | -290.18 | -- | -208.63 | 0.0331 | -- | -4.24 | -1.45 | -3.23 | -- | 60.39 | -- |
| Percheron Therapeutics Ltd | 615.48k | -11.92m | 88.35m | 8.00 | -- | 9.44 | -- | 143.55 | -0.0135 | -0.0135 | 0.0007 | 0.0104 | 0.045 | -- | 0.2912 | -- | -87.09 | -75.92 | -122.82 | -89.91 | -- | -- | -1,936.57 | -4,028.81 | -- | -1,956.65 | 0.0042 | -- | 59.90 | 56.21 | -4.74 | -- | -- | -- |
| Argenica Therapeutics Ltd | 192.09k | -5.48m | 100.44m | -- | -- | 7.00 | -- | 522.85 | -0.0518 | -0.0518 | 0.0019 | 0.1128 | 0.0148 | -- | 0.7326 | -- | -42.28 | -- | -50.70 | -- | -- | -- | -2,852.56 | -- | -- | -21,829.87 | 0.00 | -- | 214.90 | -- | -13.80 | -- | -- | -- |
| LTR Pharma Ltd | 49.00k | -6.95m | 150.08m | -- | -- | 83.92 | -- | 3,062.79 | -0.0499 | -0.0499 | 0.0004 | 0.0211 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -14,192.84 | -- | -- | -414.02 | 0.00 | -- | -- | -- | -378.00 | -- | -- | -- |
| Cogstate Ltd | 64.21m | 8.06m | 168.28m | 61.00 | 20.90 | 2.75 | 13.90 | 2.62 | 0.0467 | 0.0467 | 0.371 | 0.3543 | 0.7762 | -- | 4.96 | -- | 9.74 | 8.45 | 12.51 | 12.30 | 55.96 | 53.13 | 12.55 | 10.75 | -- | -- | 0.0162 | 0.00 | 7.36 | 14.72 | 52.75 | -- | -5.00 | -- |
| Arovella Therapeutics Ltd | 155.73k | -8.75m | 168.28m | 14.00 | -- | 14.97 | -- | 1,080.62 | -0.0093 | -0.0093 | 0.0002 | 0.0107 | 0.0166 | -- | 30.42 | -- | -93.26 | -78.61 | -116.36 | -96.29 | 100.00 | 51.81 | -5,616.16 | -2,126.97 | -- | -1,012.45 | 0.00 | -- | -64.27 | -34.07 | 14.10 | -- | -37.76 | -- |
| Dimerix Ltd | 583.48k | -17.08m | 211.67m | 0.00 | -- | 11.50 | -- | 362.77 | -0.0373 | -0.0373 | 0.0013 | 0.0331 | 0.0234 | -- | 0.0612 | -- | -68.53 | -71.97 | -98.37 | -113.16 | -- | -- | -2,926.42 | -8,332.83 | -- | -- | 0.0082 | -- | 1,485.97 | 100.27 | -23.71 | -- | 17.99 | -- |
| Race Oncology Ltd | 832.58k | -13.82m | 282.05m | -- | -- | 15.39 | -- | 338.77 | -0.0839 | -0.0839 | 0.0051 | 0.1075 | 0.0355 | -- | 0.9201 | -- | -58.97 | -46.49 | -63.04 | -48.68 | -- | -- | -1,659.82 | -2,995.74 | -- | -- | 0.00 | -- | 40.68 | 116.86 | -39.26 | -- | -- | -- |
| Imugene Ltd | 0.00 | -149.68m | 386.74m | 0.00 | -- | 3.22 | -- | -- | -0.0211 | -0.0211 | 0.00 | 0.0162 | 0.00 | -- | -- | -- | -85.91 | -44.42 | -95.62 | -47.46 | -- | -- | -- | -- | -- | -- | 0.0053 | -- | -- | -- | -294.78 | -- | 136.28 | -- |
| Immutep Ltd | 119.62k | -42.72m | 486.63m | 19.00 | -- | 2.59 | -- | 4,068.09 | -0.0353 | -0.0353 | 0.0001 | 0.1293 | 0.0007 | -- | 0.655 | -- | -24.48 | -31.68 | -25.99 | -33.91 | -- | -- | -35,710.27 | -1,829.94 | -- | -- | 0.0083 | -- | -37.61 | -54.35 | -7.07 | -- | 86.40 | -- |
Data as of Sep 20 2024. Currency figures normalised to Imugene Ltd's reporting currency: Australian Dollar AUD
6.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Sep 2024 | 240.81m | 3.28% |
| Vanguard Investments Australia Ltd.as of 31 Jul 2024 | 109.92m | 1.50% |
| Netwealth Investments Ltd.as of 26 Aug 2023 | 60.58m | 0.82% |
| BlackRock Asset Management North Asia Ltd.as of 31 Jul 2024 | 22.16m | 0.30% |
| DFA Australia Ltd.as of 31 Jul 2024 | 17.82m | 0.24% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 14.34m | 0.20% |
| Charles Schwab Investment Management, Inc.as of 05 Sep 2024 | 13.21m | 0.18% |
| SSgA Funds Management, Inc.as of 05 Sep 2024 | 10.30m | 0.14% |
| BlackRock Investment Management (Australia) Ltd.as of 05 Sep 2024 | 4.43m | 0.06% |
| Russell Investment Management Ltd.as of 28 Jun 2024 | 4.04m | 0.06% |
More ▼
Data from 30 Jun 2024 - 12 Sep 2024Source: FactSet Research Systems Inc.
